Skip to content
The state legislatures have been as busy as ever in 2023—especially in the health care sector. Now, as many legislatures across the country are […]
What’s been happening in state legislatures on health care Read More »
The 340B Program has grown exponentially as hospitals take advantage of the opportunity to profit from drug discounts while the low-income and uninsured patients
BIO tells Senators the 340B program needs reforms so it helps patients Read More »
A June 21 House hearing on health care costs put a sharp focus on the need for transparency to prevent pharmacy benefit managers (PBMs)
House hearing puts focus on need for PBM transparency Read More »
Key legislation providing greater transparency and oversight into the 340B federal drug program moved forward in the U.S. House on May 25. The House
340B legislation advances in U.S. House Read More »
U.S. Senators have been busy this week understanding and pushing forward PBM reform. On May 10, the Senate Health, Education, Labor, and Pensions (HELP) Committee
Senate HELP Committee advances PBM reform Read More »
The Senate Health, Education, Labor, and Pension (HELP) Committee on May 2 discussed Senate Bill 1339, “The Pharmacy Benefit Manager Reform Act,” and three
Vote on Pharmacy Benefit Manager Reform Act delayed until May 11 Read More »
It is already shaping up to be a tough year for Pharmacy Benefit Managers (PBMs) as federal regulators and politicians work to shed light
PBM roundup: the top 6 actions to watch Read More »
On Friday, April 14, the Biotechnology Innovation Organization (BIO) weighed in on initial guidance regarding the Drug Price Negotiation Program (Negotiation Program) under the
BIO submits comments on IRA’s Medicare Drug Price Negotiation Program Read More »
On April 18, the House Energy and Commerce Innovation, Data, and Commerce Subcommittee held a hearing on the Federal Trade Commission’s (FTC) budget for
House Energy & Commerce subcommittee spotlights ‘unfair’ PBM practices Read More »
Orphan drugs are the fastest-growing segment of the pharmaceutical market, but the Inflation Reduction Act (IRA) clouds the future of new treatments for rare
Report sees booming orphan drug market threatened by price controls Read More »
